Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

Cocrystal Pharma, Inc. operates as a biotechnology company. The Company focuses on developing novel antiviral therapeutics for hepatitis, influenza viruses, and noroviruses. Cocrystal Pharma serves patients in the United States.

<ul><li>On July 18, 2024, Cocrystal Pharma, Inc. (COCP) reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of the Phase 1 study of CDI-988, the company's pan-viral protease inhibitor that is being developed as a treatment of norovirus and coronavirus.</li><li>The single center, randomized, double blind Phase 1 trial is evaluating the safety, tolerability, and pharmacokinetics of CDI-988 compared to placebo in healthy adults in doses ranging from 100 mg to 600 mg.</li><li>The results showed that all participants completed the study with no discontinuations and there were no serious adverse events or severe treatment-emergent adverse events.</li></ul>

On July 18, 2024, Cocrystal Pharma, Inc. (COCP) reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of the Phase 1 study of CDI-988, the company's pan-viral protease inhibitor that is being developed as a treatment of norovirus and coronavirus.The single center, randomized, double blind Phase 1 trial is evaluating the safety, tolerability, and pharmacokinetics of CDI-988 compared to placebo in healthy adults in doses ranging from 100 mg to 600 mg.The results showed that all participants completed the study with no discontinuations and there were no serious adverse events or severe treatment-emergent adverse events.

COCP: Phase 1 Single-Ascending Dose Cohort of CDI-988 Shows it is Safe and Well Tolerated 

Longeveron Inc. operates as a clinical stage biotechnology company. The Company focuses on developing cellular therapies for specific aging-related and life-threatening conditions. Longeveron serves customers worldwide.

<ul><li>Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer's Disease.</li><li> The company announced that Lomecel B has been granted the Fast Track designation by the FDA, only a week after being granted the RMAT designation, which we believe further demonstrates the positive momentum of LGVN.</li></ul>

Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer's Disease. The company announced that Lomecel B has been granted the Fast Track designation by the FDA, only a week after being granted the RMAT designation, which we believe further demonstrates the positive momentum of LGVN.

LGVN: Alzheimer's Drug on a Roll with FDA

Tonix Pharmaceuticals Holding / Equity Bottom-Up

Tonix Pharmaceuticals Holding Corp. is a pharmaceutical company that develops therapies for disorders of the central nervous system ("CNS").  The Company develops therapies for disorders that include fibromyalgia syndrome ("FM") and post-traumatic stress disorder ("PTSD"),

<ul><li>On May 13, 2024, Tonix Pharmaceuticals Holding Corp. (TNXP) announced financial results for the first quarter of 2024 and provided a business update.</li><li>Tonix will be filing a New Drug Application (NDA) for Tonyma (TNX-102 SL cyclobenzaprine HCl) for fibromyalgia in the second half of 2024 based on positive results from the Phase 3 RELIEF and RESILIENT trials.</li><li>The company recently announced key findings from the initial phase of a market opportunity analysis for Tonmya by EVERSANA, including a high dissatisfaction rate with currently prescribed drugs for fibromyalgia patients, a high unmet need for effective therapies, and a high level of interest in Tonmya with an intended use of 40% among surveyed physicians.</li></ul>

On May 13, 2024, Tonix Pharmaceuticals Holding Corp. (TNXP) announced financial results for the first quarter of 2024 and provided a business update.Tonix will be filing a New Drug Application (NDA) for Tonyma (TNX-102 SL cyclobenzaprine HCl) for fibromyalgia in the second half of 2024 based on positive results from the Phase 3 RELIEF and RESILIENT trials.The company recently announced key findings from the initial phase of a market opportunity analysis for Tonmya by EVERSANA, including a high dissatisfaction rate with currently prescribed drugs for fibromyalgia patients, a high unmet need for effective therapies, and a high level of interest in Tonmya with an intended use of 40% among surveyed physicians.

TNXP: High Interest in Tonmya Seen in Initial Findings from Market Opportunity Analysis 

Medicus Pharma Ltd. is a clinical stage, multi-strategy holding company. The Company focuses on investing in and accelerating novel disruptive life sciences and bio-technology companies through FDA approved clinical trials. Medicus Pharma serves customers worldwide.

<ul>
<li>Medicus Pharma Ltd. (TSXV:MDCX) is focused on acquiring or partnering with life-science companies that are developing novel therapeutics for unmet healthcare needs that are already in the clinical trial stage.</li>
<li>Management plans fast-track these specific therapies through FDA clinical trials toward commercialization.</li>
<li>The company's first acquisition was SkinJect, which has a novel, patented transdermal patch for the treatment of BCC.</li>
</ul>


Medicus Pharma Ltd. (TSXV:MDCX) is focused on acquiring or partnering with life-science companies that are developing novel therapeutics for unmet healthcare needs that are already in the clinical trial stage.
Management plans fast-track these specific therapies through FDA clinical trials toward commercialization.
The company's first acquisition was SkinJect, which has a novel, patented transdermal patch for the treatment of BCC.


Medicus Pharma Ltd. - Medicus Submits Updated Phase 2 Clinical Protocol